`TOTAL PRESCRIPTIONS
`U.S. UNITS BY PRODUCT
`Q4 2012 – Q3 2014
`
`2012
`
`Q4
`
`Q1
`
`Q2
`
`Q3
`
`Q4
`
`Q1
`
`2013
`
`2014
`
`Q2
`
`Q3
`
`Total
`
`IV
`Herceptin®
`Kadcyla®¹
`Perjeta®
`
`Non-IV
`Tykerb®
`
`
`
`Total
`
`IV
`Herceptin®
`Kadcyla®
`Perjeta®
`
`Non-IV
`Tykerb®
`
`
`
`Total
`
`
`
`
`
`1,024
`
`140
`
`6,059
`
`7,223
`
`14.2%
`
`1.9%
`
`83.9%
`
`
`
`
`
`1,051
`14
`180
`
`5,336
`
`6,581
`
`16.0%
`0.2%
`2.7%
`
`81.1%
`
`
`
`
`
`992
`145
`214
`
`4,494
`
`5,845
`
`17.0%
`2.5%
`3.7%
`
`76.9%
`
`
`
`
`
`1,057
`257
`187
`
`4,000
`
`5,501
`
`19.2%
`4.7%
`3.4%
`
`72.7%
`
`
`
`
`
`1,034
`314
`217
`
`3,831
`
`5,396
`
`19.2%
`5.8%
`4.0%
`
`71.0%
`
`
`
`
`
`1,070
`299
`315
`
`3,552
`
`5,236
`
`20.4%
`5.7%
`6.0%
`
`67.8%
`
`
`
`
`
`1,200
`275
`333
`
`3,646
`
`5,454
`
`22.0%
`5.0%
`6.1%
`
`66.9%
`
`
`
`
`
`1,071
`203
`287
`
`8,499
`1,507
`1,873
`
`3,482
`
`34,400
`
`5,043
`
`21.2%
`4.0%
`5.7%
`
`69.0%
`
`
`
`
`
`46,279
`
`18.4%
`3.3%
`4.0%
`
`74.3%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`Notes & Sources:
`¹ Annual Kadcyla® prescriptions totaled 730 in 2013.
`Kadcyla® is indicated as a single agent for the treatment of people with HER2-positive metastatic breast cancer who have received prior treatment with Herceptin® and a taxane
`chemotherapy. See, e.g., Exhibit 2317. In contrast:
`Xeloda® can be used to treat colon, rectal, and other cancers. See, e.g., Exhibit 2246.
`Perjeta® received FDA approval for neoadjuvant breast cancer therapy. See, e.g., Exhibit 2211.
`Tykerb® is used to treat breast cancer, but is prescribed with a second medicine (Xeloda® or Femara®). See, e.g., Exhibit 2342.
`(These assertions and sources can be found in the report.)
`Includes brand values.
`Herceptin® includes brand HERCEPTIN 10/1998 GTC, identified in field 'Product.'
`Kadcyla® includes brand KADCYLA 02/2013 GTC, identified in field 'Product.'
`Perjeta® includes brand PERJETA 06/2012 GTC, identified in field 'Product.'
`Tykerb® includes brand TYKERB 03/2007 GSK, identified in field 'Product.'
`Values reflect field 'TRx'.
`Percentage calculated as percent of quarterly total.
`Products identified from Exhibit 2103 and Exhibit 2224.
`Data from IMS Health.
`
`IMMUNOGEN 2244, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`